Introduction
ASK1 (Apoptosis Signal-Regulating Kinase 1) is a member of the mitogen activated protein (MAP) kinase family of proteins and is involved in the regulation of apoptosis.
ASK1 is endogenously expressed at low levels so the vast majority of experimental work characterising ASK1 has been performed in transfected cell lines. The human ASK1 protein consists of 1375 amino acids with a serine/threonine kinase domain in the middle of the molecule (1) . The N and C-terminals of ASK1 are coiled-coil domains (1) to which regulatory molecules such as thioredoxin and glutaredoxin bind respectively to inhibit ASK1 kinase activity (2) . ASK1 has been shown to be regulated by ubiquitination, inactive ASK1 with bound thioredoxin is a target for degradation by the proteasome (3).
The majority of studies of ASK1's regulation and interaction with the apoptotic pathways has been performed in cell lines transfected with the pcDNA3-ASK1-HA plasmid (4) .
While these studies are useful in elucidating the function of ASK1 and its role in the apoptotic pathways, such artificially high levels of ASK1 may produce different results to endogenous levels of ASK1. We have examined the endogenous expression of ASK1 in a panel of non-transfected cell lines and have found that ASK1 is cleaved into two major fragments which may represent a novel mechanism of inactivation in non-apoptotic cells.
Methods

Cell Culture
The human cancer cell lines H69, CEM, U87-MG were obtained from the ATCC (Virginia, USA). were seeded for drug treatment such that the control flasks would reach confluence after 48 hours.
Transfection of ASK1 into H69 cells
The pcDNA3-ASK1-HA plasmid was a gift from Dr. Hidenori Ichijo (4 complete protease inhibitor (Roche, Sydney, Australia) was added prior to sonnication.
20µg protein was then electrophoresed and Western blotted as previously described (5) 
Results
Endogenous ASK1 is cleaved
ASK1 was examined by Western blot using a C-terminal ASK1 antibody in H69, CEM, and U87-MG cancer cell lines and in HUVEC endothelial cells ( Figure 1A ). This revealed a prominent 39kDa band in all cell lines, a 50kDa band and some multi-banding in the 150kDa range, the size of full-length ASK1, in the U87-MG and HUVEC cells. A low molecular weight fragment of ASK1 has not been previously reported in the literature so we investigated the specificity of the antibody. The major 39kDa and 50kDa
bands as well as the higher molecular weight minor bands were absent on incubation with an inhibition peptide, the epitope of the antibody ( Figure 1B) . A blast search of human protein sequences also confirmed that the C-terminal antibody's epitope was specific to human ASK1 (6). Another C-terminal ASK1 antibody (Santa Cruz Biotechnology) was tested on the H69 cells and the same 39kDa band was detected (data not shown),
suggesting that the 39kDa band was not an artefact of individual antibody.
An N-terminal ASK1 antibody detected 2 prominent bands both smaller than 150kDa
( Figure 1C ). The molecular weights of the C and N-terminal fragments were calculated and averaged from at least 5 independent Western blots using 2 different molecular weight markers for quantitation ( Figure 1D ). When the size of the major and minor bands were added from both the C and N-terminal, the total approaches the molecular weight of full-length ASK1. Figure 1E suggests potential cleavage sites determined by the size of the fragments using the data from Figure 1D using the protein size calculator Protcalc (7).
This suggests that there are several cleavage sites which may cleave and inactivate the kinase domain or alter the normal regulation of kinase activity. The C-terminal of the protein is cleaved away into the 39kDa fragment and the kinase domain may also be cleaved forming the 50kDa fragment.
As a control the pcDNA3-ASK1-HA plasmid (4) was transfected into H69 cells to test if full-length ASK1 could be detected using the C-terminal ASK1 (upstate) antibody ( Figure 1F ). The 39kDa band is present in all samples, the 150kDa band is present in the ASK1 transfected sample 72 hours after transfection and not in any of the transfection controls. This indicates that the C-terminal ASK1 antibody is capable of detecting fulllength ASK1 when it is overexpressed.
Modulation of ASK1 cleavage products in response to cisplatin
Cells were treated with 5µg/ml cisplatin for 48 hours, a dose high enough to trigger cell cycle arrest and apoptosis. The amount of the 39kDa C-terminal ASK1 band decreased in response to cisplatin treatment in the H69 and CEM cells which have mutant p53 ( Figure   2A ). Some faint bands were also observed in the ~150kDa region in response to cisplatin treatment suggesting that some full-length ASK1 may be present in the apoptotic samples. Earlier and later time points were also examined, however, no clear 150kDa ASK1 band was detected. There was no change in amount of the 39 or 50kDa bands in wild type p53 cells U87-MG and HUVEC.
Is the proteasome responsible for ASK1 cleavage?
ASK1 is inactivated by ubiquitination and degradation in cell lines which have been transfected with ASK1 (3). As the 39kDa band was so sharp we theorised that it was the product of a specific cleavage rather than degradation by the proteasome. H69 cells were treated with 10µM MG132 a reversible proteasome inhibitor for 24 and 48 hours. As a positive control for proteasome inhibition the accumulation of cell cycle protein p21 was examined ( Figure 3A) . The 48-hour MG132 treatment caused an accumulation of p21
suggesting successful proteasome inhibition and the C-terminal ASK1 fragment disappeared. This suggested that the proteasome may be involved in the degradation of endogenous ASK1. However, MG132 is also known to inhibit certain lysosomal cysteine proteases and calpains and have apoptotic activity (8) . Therefore another proteasome inhibitor lactacystin was used to confirm the involvement of the proteasome. Leupeptin which inhibits the calpains, trypsin and cathepsins (9) was also used to examine the role of these proteases. H69 cells were treated with 10µM lactacystin or 8µg/ml leupeptin for 48 hours ( Figure 3B ). No reversal of ASK1 cleavage was observed suggesting that the proteasome, calpains, trypsin and cathepsins are not involved in ASK1 cleavage.
Discussion
Why have these ASK1 fragments not been previously reported?
Although full-length 150kDa ASK1 was easily detected in ASK1-transfected cells by an antibody to the C-terminal of ASK1, it was not detected in the non-transfected cells. 
Endogenous ASK1 is not cleaved by the proteasome
The proteasome is not responsible for ASK1 cleavage as lactacystin did not reverse the cleavage. The proteasome is also unlikely to be involved as its function is to degrade proteins into small peptides of 3-20 residues not produce large protein fragments which could be biologically active (8) . ASK1 is either cleaved by a protease which is inhibited 11 by MG132 (Figure 3 ) or MG132 is having an apoptotic effect and reversing the cleavage in a similar manner to the treatment with cisplatin ( Figure 2 ).
Conclusions
Endogenous ASK1 is normally cleaved in cells, this cleavage is specific and may inactivate the kinase domain of the protein. The degradation of endogenous ASK1 is independent of the proteasome which is different to the degradation characterised for transfected ASK1. Transfected ASK1 may therefore not accurately model endogenous ASK1.
